NFS-01 (NR082/rAAV2-ND4)
Leber's Hereditary Optic Neuropathy (LHON) due to ND4 mutation
Phase 3Active, with ongoing trials in China and U.S. Phase I/II completed enrollment
Key Facts
Indication
Leber's Hereditary Optic Neuropathy (LHON) due to ND4 mutation
Phase
Phase 3
Status
Active, with ongoing trials in China and U.S. Phase I/II completed enrollment
Company
About Neurophth Therapeutics
China's leading ocular gene therapy company developing AAV-based treatments for inherited retinal diseases like LHON.
View full company profile